NCT06955390View on ClinicalTrials.gov

Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Solid Tumors
Interventions
DRUG

SHR-A2102+HRS-4642

A fixed dose was used for SHR-A2102,HRS-4642 can be dose adjusted.

Trial Locations (1)

Unknown

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT06955390 - Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter